TCG Labs-Soleil

What TCG Labs-Soleil does

TCG Labs-Soleil is a venture-backed biotech that operates an integrated venture-capital-plus-R&D model established in 2024 in collaboration with The Column Group. It combines a dedicated venture fund (TCG Labs, with $800 million committed across two tranches in 2024 and 2025) with an evergreen R&D hub (Soleil) staffed by veteran scientists from Amgen, Genentech, NGM Biopharmaceuticals, Tularik, and Merck. The organization forms and oversees more than ten wholly-owned, single-asset portfolio companies across oncology, immunology, cardiometabolic, respiratory, neurology, and obesity indications, advancing biologic programs (monoclonal antibodies, bispecifics, and T-cell engagers) from ideation through clinical proof of concept.

Soleil maintains full-stack drug development capabilities in-house, including discovery research, translational science, clinical development, regulatory affairs, CMC, and nonclinical safety assessment, plus dedicated business development. Programs are deliberately structured as standalone portfolio companies to enable focused execution and simple strategic transactions. The flagship disclosed asset, a KLK2-directed T-cell engager developed by portfolio company Juri Biosciences, was outlicensed to EpimAb Biotherapeutics in May 2025 in a deal worth up to $210 million in upfront, milestone, and royalty payments, establishing the licensing-to-pharma channel as the primary revenue realization mechanism.

TCG Labs-Soleil does not sell products directly; revenue is generated through licensing transactions and strategic sales of portfolio company assets to large pharmaceutical and biotechnology partners, with pricing negotiated case-by-case. The company is headquartered in South San Francisco and expanded to a Shanghai R&D presence in 2025, supporting both internally generated and externally sourced programs sourced from scientific founders and academic institutions globally.

Name

TCG Labs-Soleil

Legal name

TCG Labs Fund I, LP and Soleil Labs, LLC

Website

https://tcglsoleil.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

51–100 employees

Short description

TCG Labs-Soleil is a venture-backed biotech that combines an $800M venture fund from The Column Group with an evergreen R&D hub to form and develop single-asset portfolio companies, outlicensing biologic programs to pharmaceutical partners after clinical proof of concept.

Ownership category

akta.pro rank

Product category

Biopharmaceutical R&D

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Joint Venture CVC / Consortium Funds (Multi-corporate) (FSANAHAE)

akta.pro secondary industries

Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Venture biotech
• Biologics drug discovery
• Single-asset therapeutics
• Strategic licensing transactions
• Clinical proof of concept

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Strategic Transactions and Licensing: Portfolio companies are guided from ideation to clinical proof of concept, then positioned for strategic partnerships and licensing deals with large biotech and pharmaceutical companies. Revenue generated through upfront payments, milestone payments, and royalties from these transactions.
2. Venture Fund Returns: Returns generated through equity ownership in portfolio companies, with value realized through strategic transactions, acquisitions, or IPOs.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

TCG Labs-Soleil forms and oversees independent portfolio companies, each focused on a single biologic therapeutic candidate, guiding programs from ideation through clinical proof of concept. The company integrates a dedicated venture fund (TCG Labs) with an evergreen R&D hub (Soleil) staffed by top-tier scientists, then positions these de-risked single-asset programs for strategic licensing and partnership transactions with large pharmaceutical and biotechnology companies. Revenue is generated through upfront payments, milestone payments, and royalties from these licensing agreements, along with equity returns from portfolio company transactions.

Product overview

TCG Labs Soleil operates a pioneering venture-biotech model that integrates TCG Labs (a dedicated venture fund) with Soleil (an evergreen R&D hub led by top-tier scientists). The company forms and oversees independent portfolio companies—Juri Biosciences, Duboce Biopharmaceuticals, Arguello Biosciences, Fulton Therapeutics, Clement Therapeutics, Highland Therapeutics, Irving Life Sciences, and Natoma Biosciences—each dedicated to single-asset biologic programs spanning oncology, immunology, autoimmune diseases, metabolic disorders, and other therapeutic areas. The ecosystem guides programs from ideation through clinical proof of concept, positioning them for strategic transactions with pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Products and services

• TCG Labs (Venture Fund) TCG Labs is the dedicated venture fund that provides exclusive funding for single-asset biologic programs, integrated with the Soleil R&D hub to advance therapies from ideation through clinical proof of concept. Designed for scientific founders, academic institutions, and partners with innovative therapeutic concepts.
• Soleil (Evergreen R&D Hub) Soleil is the evergreen independent R&D hub led by top-tier scientists that establishes and oversees portfolio companies focused on single-asset biologic programs, providing drug discovery expertise from bench to clinical validation. Staffed by veteran drug developers from Amgen, Genentech, NGM Biopharmaceuticals, and other leading organizations.
• Juri Biosciences, Inc. Portfolio company developing a KLK2-directed T-cell engager and second-generation KLK2 molecule for metastatic prostate cancer, currently at IND-enabling stage. Subject of a May 2025 worldwide licensing agreement with EpimAb Biotherapeutics worth up to $210 million.
• Duboce Biopharmaceuticals, Inc. Portfolio company focused on oncology therapeutics development under TCG Labs-Soleil's single-asset program model.
• Arguello Biosciences, Inc. Portfolio company developing a Factor XI monoclonal antibody for atrial fibrillation and other thromboembolic diseases.
• Fulton Therapeutics, Inc. Portfolio company focused on immunology therapeutics development.
• Clement Therapeutics, Inc. Portfolio company developing a TSLP x IL33 bispecific antibody for COPD, asthma, and CRSwNP (chronic rhinosinusitis with nasal polyps).
• Highland Therapeutics, Inc. Portfolio company developing a CGRP x PACAP bispecific antibody for migraine prevention.
• Irving Life Sciences, Inc. Portfolio company in preclinical stage of therapeutic development.
• Natoma Biosciences, Inc. Portfolio company focused on obesity therapeutics development.

Quantifiable outcome

• Up to $210 million in potential deal value from licensing agreements
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered flagship and core.

• EpimAb BiotherapeuticsflagshipStrategic or Co-development Partner · 27 May 2025Juri Biosciences, a TCG Labs Soleil portfolio company, entered into a worldwide licensing agreement with EpimAb Biotherapeutics. The agreement grants Juri exclusive global rights to a development-ready T-cell engager targeting KLK2 and CD3 for metastatic prostate cancer. EpimAb is eligible to receive up to $210 million including upfront and milestone payments plus tiered royalties.
• Scientific Founders and Academic InstitutionscoreStrategic or Co-development PartnerTCG Labs Soleil actively seeks innovative ideas from scientific founders, academic institutions, and companies with early-stage assets, providing unique access to Soleil's established drug discovery team and support of TCG Labs' exclusive venture fund.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• NGM Biopharmaceuticals: NGM was co-founded by CEO Jin-Long Chen and several other TCG Labs-Soleil co-founders and operates a similar model of integrated R&D with focus on metabolic and inflammatory disease biology. Many of TCG Labs-Soleil's scientific team and approach come directly from NGM's playbook.
• Samsara BioCapital: Samsara is a life-sciences-focused venture firm that invests across stages from seed to phase three clinical trials, including creating new biotech companies. The platform is comparable to TCG Labs as the capital component of TCG Labs-Soleil's integrated model.

Broad incumbents

• Atlas Venture: Atlas Venture is a long-standing biotech creation firm that builds and funds early-stage therapeutic companies, many of which are acquired by larger pharma. It shares the venture-led biotech formation model but operates as a pure fund manager without an integrated R&D hub.
• Flagship Pioneering: Flagship Pioneering is a larger, established company creation platform that forms and funds multiple biotech ventures, including Moderna. It shares TCG Labs-Soleil's portfolio-company architecture but operates at a significantly larger scale and broader scope across multiple modalities.
• Arch Venture Partners: Arch Venture Partners is a long-established biotech creation firm that has co-founded dozens of therapeutic companies. It shares TCG Labs-Soleil's portfolio architecture of multiple single-asset ventures, though Arch operates as a pure fund manager without an in-house R&D hub.
• OrbiMed: OrbiMed is a large healthcare-dedicated investment firm that spans venture, growth, and public equity across biotech, devices, and services. While it invests broadly, its venture practice creates and backs single-asset biotech companies similar to TCG Labs-Soleil's portfolio companies.

Direct peers

• BridgeBio Pharma: BridgeBio develops a portfolio of genetically validated single-asset programs across multiple therapeutic areas and is structured to enable individual asset transactions. The model shares TCG Labs-Soleil's emphasis on focused, single-mechanism programs and licensing/strategic exit pathways.
• Medicxi: Medicxi is a venture-led biotech creation firm that builds single-asset companies with focused R&D teams and exits via licensing or M&A. The model closely mirrors TCG Labs-Soleil's venture-biotech structure, though Medicxi is purely a fund manager while TCG Labs-Soleil operates an integrated R&D hub.
• PureTech Health: PureTech runs an R&D hub that forms and oversees independent therapeutic companies, much like TCG Labs-Soleil's Soleil-to-portfolio-company pipeline. Both platforms emphasize capital efficiency, dedicated R&D infrastructure, and licensing of de-risked programs to large pharma.
• Roivant Sciences: Roivant operates a 'Vant' model creating subsidiary companies focused on individual therapeutic programs, with a centralized R&D and capital allocation structure. This is the closest analogue to TCG Labs-Soleil's single-asset portfolio company approach, though Roivant is publicly traded and has brought multiple programs to market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/soleil-labs-sf/?viewAsMember=true

Revenue estimate

Valuation estimate

Number of profiles

Profiles35 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TCG Labs-Soleil